Ann Pediatr Endocrinol Metab.  2014 Mar;19(1):32-35. 10.6065/apem.2014.19.1.32.

Efficacy of growth hormone therapy in adults with childhood-onset growth hormone deficiency

• Kim JH
• Cho JH
• Yoo HW
• Choi JH

• KMID: 1702661
• DOI: http://doi.org/10.6065/apem.2014.19.1.32

Abstract

PURPOSE
Growth hormone (GH) plays a key role in the regulation of body composition, lipid metabolism, and quality of life in adults with GH deficiency (GHD). This study investigated changes in laboratory findings and body composition after GH recommencement for adult GHD and analyzed correlation between GH interruption period and endocrine or anthropometric parameters.
METHODS
A total of 45 patients (17 females and 28 males) diagnosed with childhood-onset GHD (CO-GHD) were investigated and all patients had organic brain lesions. Patients diagnosed CO-GHD were retested to confirm adult GHD at age 20.4+/-5.0 years (18.0-32.1 years). Recombinant human GH was administered at a dose of 0.44 mg/day. Clinical and laboratory parameters such as weight, height, body mass index (BMI), serum insulin-like growth factor 1 (IGF-1), serum total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride levels, were compared between baseline and 12 months after treatment using paired t-test. In addition, correlation between GH interruption period and clinical parameters including BMI, lipid profile, IGF-1, and IGFBP-3, was analyzed.
RESULTS
Of 45 patients, 33 patients had GH interruption period of 4.3+/-3.6 years (0.7-12.5 years). Serum HDL-cholesterol level increased significantly, whereas LDL-cholesterol decreased after 1 year of GH replacement therapy. However, body weight and BMI showed no significant changes after 1 year of GH replacement therapy. There were no significant correlations between GH interruption period and lipid profile or anthropometric parameters.
CONCLUSION
BMI and body weight were not affected by GH replacement. However, GH replacement in adults with GHD offers benefits in lipid metabolism.

Keyword

Pituitary dwarfism; Body mass index; Cholesterol; Insulin-like growth factor 1

MeSH Terms

Adult*
Body Composition
Body Height
Body Mass Index
Body Weight
Brain
Cholesterol
Dwarfism, Pituitary
Female
Growth Hormone*
Humans
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor I
Lipid Metabolism
Lipoproteins
Quality of Life
Triglycerides
Cholesterol
Growth Hormone
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor I
Lipoproteins

Reference

1. Inzaghi E, Cianfarani S. The Challenge of Growth Hormone Deficiency Diagnosis and Treatment during the Transition from Puberty into Adulthood. Front Endocrinol (Lausanne). 2013; 4:34. PMID: 23577001.

2. Reed ML, Merriam GR, Kargi AY. Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement. Front Endocrinol (Lausanne). 2013; 4:64. PMID: 23761782.

3. Cook DM, Rose SR. A review of guidelines for use of growth hormone in pediatric and transition patients. Pituitary. 2012; 15:301–310. PMID: 22271255.

4. Cook DM, Yuen KC, Biller BM, Kemp SF, Vance ML. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients -2009 update. Endocr Pract. 2009; 15(Suppl 2):1–29. PMID: 20228036.

5. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96:1587–1609. PMID: 21602453.

6. Duntas LH. Thyroid disease and lipids. Thyroid. 2002; 12:287–293. PMID: 12034052.

7. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. J Clin Endocrinol Metab. 2004; 89:2192–2199. PMID: 15126541.

8. Ho KK. 2007 GH Deficiency Consensus Workshop Participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol. 2007; 157:695–700. PMID: 18057375.

9. Barake M, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab. 2014; 1. 01. jc20133921. [Epub]. http://dx.doi.org/10.1210/jc.2013-3921.

10. Kuzma M, Kuzmova Z, Zelinkova Z, Killinger Z, Vanuga P, Lazurova I, et al. Impact of the growth hormone replacement on bone status in growth hormone deficient adults. Growth Horm IGF Res. 2014; 24:22–28. PMID: 24382377.

11. Kołtowska-Häggstrom M, Geffner ME, Jonsson P, Monson JP, Abs R, Hana V, et al. Discontinuation of growth hormone (GH) treatment during the transition phase is an important factor determining the phenotype of young adults with nonidiopathic childhood-onset GH deficiency. J Clin Endocrinol Metab. 2010; 95:2646–2654. PMID: 20335451.